Testing RAP-219 to reduce seizures in focal epilepsy
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a new medication called RAP-219 to see if it can reduce seizure frequency in adults with focal epilepsy (seizures starting in one area of the brain). You'll take the medication alongside your current seizure drugs and track your seizures daily using an app.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with focal epilepsy at least 2 years ago with recent brain imaging and EEG confirming the diagnosis
- Currently taking 1–3 seizure prevention medications
- Able to record seizures daily using a smartphone or electronic diary
- No history of severe surgeries, life-threatening seizure clusters, or other serious unstable medical conditions
- Not currently in another drug trial (or at least 12 weeks since your last trial drug)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication called RAP-219 can help adults with focal seizures (seizures that start in one area of the brain) control their seizures better. You would take this medication alongside your current seizure drugs for about 12 weeks.
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.
This trial tests a mobile app called EPIDAY that gives you a daily forecast of your seizure risk. It is designed for people with focal epilepsy who have seizures at least two days a month.
Hear when a new Focal Seizure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.